Discovering a vaccine against neosporosis using computers: Is it feasible?

Trends in Parasitology

Volumn 30, Issue 8, 2014, Pages 401-411

  Goodswen, Stephen J ^a   Kennedy, Paul J ^a   Ellis, John T ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Apicomplexa; In silico vaccine discovery; Neospora caninum; Neosporosis; Reverse vaccinology; Vaccinomics

Indexed keywords

ANTIGEN; VACCINE;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; APICOMPLEXA; B LYMPHOCYTE; BRADYZOITE; CATALYST; CELL VACUOLE; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; IMMUNE RESPONSE; INFECTION CONTROL; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOSPORA CANINUM; NEOSPOROSIS; NONHUMAN; PREDICTION; PROTEIN ANALYSIS; REVIEW; VACCINATION;

APICOMPLEXA; BOS; NEOSPORA CANINUM;

APICOMPLEXA; IN SILICO VACCINE DISCOVERY; NEOSPORA CANINUM; NEOSPOROSIS; REVERSE VACCINOLOGY; VACCINOMICS;

ANIMALS; ANTIGENS, PROTOZOAN; CATTLE; CATTLE DISEASES; COCCIDIOSIS; COMPUTER SIMULATION; COMPUTERS; NEOSPORA; PROTOZOAN VACCINES;

EID: 84904725957     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2014.06.004     Document Type: Review

References (91)

1. Reichel M.P., et al. What is the global economic impact of Neospora caninum in cattle: the billion dollar question. Int. J. Parasitol. 2013, 43:133-142.
2. Reichel M.P., Ellis J.T. Re-evaluating the economics of neosporosis control. Vet. Parasitol. 2008, 156:361-362.
3. Weston J.F., et al. Efficacy of a Neospora caninum killed tachyzoite vaccine in preventing abortion and vertical transmission in dairy cattle. Prev. Vet. Med. 2012, 103:136-144.
4. Reichel M.P., Ellis J.T. Neospora caninum: how close are we to development of an efficacious vaccine that prevents abortion in cattle?. Int. J. Parasitol. 2009, 39:1173-1187.
5. Dubey J.P., Schares G. Neosporosis in animals: the last five years. Vet. Parasitol. 2011, 180:90-108.
6. Goodswen S.J., et al. A review of the infection, genetics, and evolution of Neospora caninum: from the past to the present. Infect. Genet. Evol. 2013, 13:133-150.
7. Monney T., Hemphill A. Vaccines against neosporosis: what can we learn from the past studies?. Exp. Parasitol. 2014, 140:52-70.
8. Kim J.Y., et al. Interaction between parasitophorous vacuolar membrane-associated GRA3 and calcium modulating ligand of host cell endoplasmic reticulum in the parasitism of Toxoplasma gondii. Korean J. Parasitol. 2008, 46:209-216.
9. Miller C.M., et al. The immunobiology of the innate response to Toxoplasma gondii. Int. J. Parasitol. 2009, 39:23-39.
10. Williams D.J.L., et al. Endogenous and exogenous transplacental transmission of Neospora caninum: how the route of transmission impacts on epidemiology and control of disease. Parasitology 2009, 136:1895-1900.
11. Reichel M.P., et al. Control options for Neospora caninum: is there anything new or are we going backwards?. Parasitology 2014, 10.1017/S0031182014000158.
12. Dubey J.P., et al. Pathogenesis of bovine neosporosis. J. Comp. Pathol. 2006, 134:267-289.
13. Innes E.A., et al. The host-parasite relationship in bovine neosporosis. Vet. Immunol. Immunopathol. 2005, 108:29-36.
14. Andrianarivo A.G., et al. Immune responses during pregnancy in heifers naturally infected with Neospora caninum with and without immunization. Parasitol. Res. 2005, 96:24-31.
15. Rosbottom A., et al. Upregulation of cytokines is detected in the placentas of cattle infected with Neospora caninum and is more marked early in gestation when fetal death is observed. Infect. Immun. 2008, 76:2352-2361.
16. Williams D.J.L., et al. Immunization of cattle with live tachyzoites of Neospora caninum confers protection against fetal death. Infect. Immun. 2007, 75:1343-1348.
17. Williams D.J.L., et al. First demonstration of protective immunity against foetopathy in cattle with latent Neospora caninum infection. Int. J. Parasitol. 2003, 33:1059-1065.
18. Alaeddine F., et al. Reduced infection and protection from clinical signs of cerebral neosporosis in C57BL/6 mice vaccinated with recombinant microneme antigen NcMIC1. J. Parasitol. 2005, 91:657-665.
19. Bartley P.M., et al. Maternal and foetal immune responses of cattle following an experimental challenge with Neospora caninum at day 70 of gestation. Vet. Res. 2012, 43:38.
20. Cho J-H., et al. Protective efficacy of vaccination with Neospora caninum multiple recombinant antigens against experimental Neospora caninum infection. Korean J. Parasitol. 2005, 43:19-25.
21. Debache K., et al. Intraperitoneal and intra-nasal vaccination of mice with three distinct recombinant Neospora caninum antigens results in differential effects with regard to protection against experimental challenge with Neospora caninum tachyzoites. Parasitology 2010, 137:229-240.
22. Ellis J., et al. Evaluation of recombinant proteins of Neospora caninum as vaccine candidates (in a mouse model). Vaccine 2008, 26:5989-5996.
23. Haldorson G.J., et al. Immunization with native surface protein NcSRS2 induces a Th2 immune response and reduces congenital Neospora caninum transmission in mice. Int. J. Parasitol. 2005, 35:1407-1415.
24. Pinitkiatisakul S., et al. Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations. Vaccine 2007, 25:3658-3668.
25. Ramamoorthy S., et al. Prevention of vertical transmission of Neospora caninum in C57BL/6 mice vaccinated with Brucella abortus strain RB51 expressing N-caninum protective antigens. Int. J. Parasitol. 2007, 37:1531-1538.
26. Nishikawa Y., et al. In the absence of endogenous gamma interferon, mice acutely infected with Neospora caninum succumb to a lethal immune response characterized by inactivation of peritoneal macrophages. Clin. Diagn. Lab. Immunol. 2001, 8:811-817.
27. Staska L.M., et al. Identification of vaccine candidate peptides in the NcSRS2 surface protein of Neospora caninum by using CD4(+) cytotoxic T lymphocytes and gamma interferon-secreting T lymphocytes of infected Holstein cattle. Infect. Immun. 2005, 73:1321-1329.
28. Ferreirinha P., et al. Protective effect of intranasal immunization with Neospora caninum membrane antigens against murine neosporosis established through the gastrointestinal tract. Immunology 2014, 141:256-267.
29. Haldorson G.J., et al. Neospora caninum: antibodies directed against tachyzoite surface protein NcSRS2 inhibit parasite attachment and invasion of placental trophoblasts in vitro. Exp. Parasitol. 2006, 112:172-178.
30. Uchida Y., et al. Monoclonal antibodies preventing invasion of Neospora caninum tachyzoites into host cells. J. Vet. Med. Sci. 2004, 66:1355-1358.
31. Zhang H., et al. Apical membrane antigen 1 is a cross-reactive antigen between Neospora caninum and Toxoplasma gondii, and the anti-NcAMA1 antibody inhibits host cell invasion by both parasites. Mol. Biochem. Parasitol. 2007, 151:205-212.
32. Goodswen S.J., et al. Evaluating high-throughput ab initio gene finders to discover proteins encoded in eukaryotic pathogen genomes missed by laboratory techniques. PLoS ONE 2012, 7:e50609.
33. Serruto D., et al. Genome-based approaches to develop vaccines against bacterial pathogens. Vaccine 2009, 27:3245-3250.
34. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001, 19:2688-2691.
35. Rinaudo C.D., et al. Vaccinology in the genome era. J. Clin. Invest. 2009, 119:2515-2525.
36. Ariel N., et al. Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect. Immun. 2002, 70:6817-6827.
37. Montigiani S., et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. 2002, 70:368-379.
38. Ross B.C., et al. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 2001, 19:4135-4142.
39. Serruto D., et al. Meningococcus B: from genome to vaccine. Genomics, Proteomics and Vaccines 2004, 185-204. John Wiley & Sons Ltd. G. Grandi (Ed.).
40. Wizemann T.M., et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 2001, 69:1593-1598.
41. Jones D. Reverse vaccinology on the cusp. Nat. Rev. Drug Discov. 2012, 11:175-176.
42. Mutapi F., et al. Infection and treatment immunizations for successful parasite vaccines. Trends Parasitol. 2013, 29:135-141.
43. Goodswen S.J., et al. A guide to in silico vaccine discovery for eukaryotic pathogens. Brief. Bioinform. 2013, 14:753-774.
44. Wang P., et al. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 2008, 4:e1000048.
45. Lundegaard C., et al. State of the art and challenges in sequence based T-cell epitope prediction. Immunome Res. 2010, 6(Suppl. 2):S3.
46. Bui H-H., et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005, 57:304-314.
47. Juliarena M.A., et al. Association of BLV infection profiles with alleles of the BoLA-DRB3.2 gene. Anim. Genet. 2008, 39:432-438.
48. Kulberg S., et al. Study on the association of BoLA-DRB3.2 alleles with clinical mastitis in Norwegian Red cows. J. Anim. Breed. Genet. 2007, 124:201-207.
49. Robinson J., et al. IPD: the Immuno Polymorphism Database. Nucleic Acids Res. 2013, 41:D1234-D1240.
50. Glass E.J., et al. Duplicated DQ haplotypes increase the complexity of restriction element usage in cattle. J. Immunol. 2000, 165:134-138.
51. Miyasaka T., et al. The diversity of bovine MHC class II DRB3 and DQA1 alleles in different herds of Japanese Black and Holstein cattle in Japan. Gene 2011, 472:42-49.
52. Takeshima S., et al. Evidence for cattle major histocompatibility complex (BoLA) class II DQA1 gene heterozygote advantage against clinical mastitis caused by Streptococci and Escherichia species. Tissue Antigens 2008, 72:525-531.
53. Schwab A.E., et al. Association of BoLA DRB3 and DQA1 alleles with susceptibly to Neospora caninum and reproductive outcome in Quebec Holstein cattle. Vet. Parasitol. 2009, 165:136-140.
54. Reid A.J., et al. Comparative genomics of the apicomplexan parasites Toxoplasma gondii and Neospora caninum: coccidia differing in host range and transmission strategy. PLoS Pathog. 2012, 8:e1002567.
55. Dubey J.P., et al. Epidemiology and control of neosporosis and Neospora caninum. Clin. Microbiol. Rev. 2007, 20:323.
56. Rappuoli R. Reverse vaccinology. Curr. Opin. Microbiol. 2000, 3:445-450.
57. Nielsen M., et al. NetMHCIIpan-2.0: improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res. 2010, 6:9.
58. Yao B., et al. Conformational B-cell epitope prediction on antigen protein structures: a review of current algorithms and comparison with common binding site prediction methods. PLoS ONE 2013, 8:e62249.
59. Yang X., Yu X. An introduction to epitope prediction methods and software. Rev. Med. Virol. 2009, 19:77-96.
60. EL-Manzalawy Y., Honavar V. Recent advances in B-cell epitope prediction methods. Immunome Res. 2010, 6:S2.
61. Liang S., et al. EPSVR and EPMeta: prediction of antigenic epitopes using support vector regression and multiple server results. BMC Bioinformatics 2010, 11:381.
62. Flower D.R., et al. Computer aided selection of candidate vaccine antigens. Immunome Res. 2010, 6(Suppl. 2):S1.
63. Leuzzi R., et al. Genome mining and reverse vaccinology. Handbook of Meningococcal Disease: Infection Biology, Vaccination, Clinical Management 2006, 391-402. Wiley-VCH Verlag GmbH & Co. M. Frosch, M.C.J. Maiden (Eds.).
64. Mora M., et al. Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr. Opin. Microbiol. 2006, 9:532-536.
65. Serino L., et al. Reverse vaccinology: revolutionizing the approach to vaccine design. Pathogenomics 2006, 533-554. Wiley-VCH Verlag GmbH & Co. J. Hacker, U. Dobrindt (Eds.).
66. Vivona S., et al. Computer-aided biotechnology: from immuno-informatics to reverse vaccinology. Trends Biotechnol. 2008, 26:190-200.
67. Goodswen S., et al. A novel strategy for classifying the output from an in silico vaccine discovery pipeline for eukaryotic pathogens using machine learning algorithms. BMC Bioinformatics 2013, 14:315.
68. Pulendran B., et al. Systems vaccinology. Immunity 2010, 33:516-529.
69. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 2009, 9:741-747.
70. Rotem S., et al. Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8(+) T cell epitopes. PLoS ONE 2014, 9:e85215.
71. Zvi A., et al. Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response. PLoS ONE 2011, 6:e20050.
72. Schroeder J., Aebischer T. Vaccines for leishmaniasis: from proteome to vaccine candidates. Hum. Vaccin. 2011, 7:10-15.
73. He Y., et al. Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J. Biomed. Biotechnol. 2010, 10.1155/2010/297505.
74. Vivona S., et al. NERVE: New Enhanced Reverse Vaccinology Environment. BMC Biotechnol. 2006, 6:35.
75. Goodswen S.J., et al. Vacceed: a high-throughput in silico vaccine candidate discovery pipeline for eukaryotic pathogens based on reverse vaccinology. Bioinformatics 2014, 10.1093/bioinformatics/btu300.
76. Rappuoli R., Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011, 473:463-469.
77. Donati C., Rappuoli R. Reverse vaccinology in the 21st century: improvements over the original design. Year Immunol. 2013, 1285:115-132.
78. Dormitzer P.R., et al. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 2008, 26:659-667.
79. McAllister M.M. Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs. Parasitology 2014, 141:624-640.
80. Bijker M.S., et al. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev. Vaccines 2007, 6:591-603.
81. Rapin N., et al. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS ONE 2010, 5:e9862.
82. Folcik V.A., et al. The basic immune simulator: an agent-based model to study the interactions between innate and adaptive immunity. Theor. Biol. Med. Model. 2007, 4:39.
83. Kalita J.K., et al. Computational modelling and simulation of the immune system. Int. J. Bioinform. Res. Appl. 2006, 2:63-88.
84. Reed S.G., et al. New horizons in adjuvants for vaccine development. Trends Immunol. 2009, 30:23-32.
85. Innes E.A., et al. Immune responses to Neospora caninum and prospects for vaccination. Trends Parasitol. 2002, 18:497-504.
86. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10:787-796.
87. Coffman R.L., et al. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
88. Mineo T.W.P., et al. Recognition by toll-like receptor 2 induces antigen-presenting cell activation and Th1 programming during infection by Neospora caninum. Immunol. Cell Biol. 2010, 88:825-833.
89. Liu M.A. DNA vaccines: an historical perspective and view to the future. Immunol. Rev. 2011, 239:62-84.
90. Chong S.F., et al. A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. Biomaterials 2009, 30:5178-5186.
91. Kudela P., et al. Bacterial ghosts (BGs)-Advanced antigen and drug delivery system. Vaccine 2010, 28:5760-5767.